BWX Technologies (BWXT), a U.S. government nuclear components supplier, has completed its previously announced purchase of Sotera Health's Nordion medical isotope business.
The acquisition adds approximately 150 personnel, two specialized production centers, and a licensed infrastructure that will de-risk BWXT's entry into the medical radioisotope market, according to the vendor.
The Nordion team, infrastructural assets, and channels will be used to market BWXT's previously announced molybdenum-99 product line, as well as a number of future radioisotope-based imaging and therapeutic products, the company said. BWXT also emphasized that current medical isotope and contract manufacturing operations will not be disrupted as a result of the deal.
Tom Burnett, vice president and general manager of BWXT ITG Canada, will lead the company's new medical isotope business, which will be included in BWXT's nuclear power group segment.
